Skip to content
lifestyle.celebhomes.net
Author:
InflaRx N.V.
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
April 28, 2026
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
April 9, 2026
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
March 31, 2026
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
March 30, 2026
←
Previous Page
1
2